<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04827628</url>
  </required_header>
  <id_info>
    <org_study_id>1803211718</org_study_id>
    <nct_id>NCT04827628</nct_id>
  </id_info>
  <brief_title>Effect of Oryza Sativa l Extract to LPS, ZO-1, and Intestinal Microbiota in Obese Individuals</brief_title>
  <official_title>Effect of Oryza Sativa l Extract to Serum Lipopolysaccharide, Tight Junction Protein 1 (ZO-1), and Intestinal Microbiota Expression Among Obese Individual</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasanuddin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hasanuddin University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background :&#xD;
&#xD;
      Obesity prevalence rises among adults and leads to morbidity and mortality due to subsequent&#xD;
      inflammation pathway activation. This activation is induced by higher lipid consumption which&#xD;
      activates the Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway&#xD;
      and alters the microbiota profile. The Oryza sativa extract contains anthocyanin which&#xD;
      possibly affects the microbiota composition and NF-kb pathway which eventually preserves the&#xD;
      protective layer and tight junction of the epithelial cells. Therefore it is important to&#xD;
      address the impact of this extract on these parameters.&#xD;
&#xD;
      Objective :&#xD;
&#xD;
      To assess the effect of Oryza sativa extract on microbiota profile (Lactobacillus,&#xD;
      Firmicutes, Bacteroides, Bifidobacteria, and Escherichia coli), Lipopolysaccharide/ LPS, and&#xD;
      the tight epithelial junction (Zonula Occludens-1) among obese adults.&#xD;
&#xD;
      Method:&#xD;
&#xD;
      A two-arm Quasi-Experimental will be conducted, followed by two repeated measurements, at the&#xD;
      baseline and 3 weeks after intervention&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      Oryza sativa extract lowers the LPS level, Firmicutes sp, Bacteroides sp, and increases ZO1&#xD;
      protein, Bifidobacteria, and Lactobacillus sp.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Method:&#xD;
&#xD;
        1. Non Randomized clinical trial with double-blind&#xD;
&#xD;
        2. Participants will be recruited consecutively&#xD;
&#xD;
        3. Matching technique will be applied following several variables adjustment&#xD;
&#xD;
        4. Two-arm of the group participants are the normal group, the obese control group, and the&#xD;
           obese intervention group&#xD;
&#xD;
      Sample size calculation:&#xD;
&#xD;
      The difference between two independent means sample size calculation is applied following the&#xD;
      elements below:&#xD;
&#xD;
      a. Type 1 error: 10% b. Power: 80% c. Effect Size: 0.9 (based on changes of LPS value) d.&#xD;
      Dropout rate: 20% e. Hypothesis: Superiority Trial g. The number of participants per group:&#xD;
      14&#xD;
&#xD;
      Intervention :&#xD;
&#xD;
        1. Extract: Liquid extract of Oryza sativa derived from 10 grams of Oryza sativa fine&#xD;
           powder. The powder is mixed with 100 ml ethanol 50% and 0.5 ml of hydrochloric acid&#xD;
           (HCl) in 300 C for 2 hours. A supernatant is extracted and evaporated at 35 C and dried&#xD;
           and 60 C to remove any dissolving agents. This yields an extract of 624.27 mg.&#xD;
&#xD;
        2. Anthocyanin level is measured using a spectrophotometer where 20 microliters of extract&#xD;
           added to 2 mL Potassium Chloride (KCl) (with pH 1.0) and 2 ml Sodium Acetate (NaCH3COO)&#xD;
           (pH 4.5). Absorption of 500 nm and 700 nm waves are measured and calculated using the&#xD;
           cyanide-3-glucoside calculation where :&#xD;
&#xD;
      anthocyanin level : (absorbance x 449.2 x dilution factor x 1000) / 26.9&#xD;
&#xD;
      Control&#xD;
&#xD;
      a. Active comparator using citric acid and sorbitol mixture&#xD;
&#xD;
      Biological sample:&#xD;
&#xD;
        1. Serum sample preparation :&#xD;
&#xD;
           Participants should undergo fasting for 12 hours. Blood is drawn from the cubital vein&#xD;
           to the plain tube and incubated for 30-45 minutes. Centrifugation of sample is done for&#xD;
           15 minutes with 3000 rotation per minute to yield the serum. The supernatant then&#xD;
           extracted and stored at -80 C.&#xD;
&#xD;
        2. Feces primary Polymerase Chain Reaction (PCR) using 100-gram feces. The PCR primer for&#xD;
           intestinal microbiota are enlisted below :&#xD;
&#xD;
             1. Total intestinal microbiota (ACTCCTACGGGAGGCAGCAGT ATTACCGCGGCTGCTGGC),&#xD;
&#xD;
             2. Firmicutes-Lactobacillus (TACATCCCAACTCCAGAACGAAGCAACAGTACCACGACC)),&#xD;
&#xD;
             3. Bacteroidetes-Bacteroides fragilis (ATAGCCTTCGAAAGRAAGATCCAGTATCAACTGCAATTTTA),&#xD;
&#xD;
             4. Actinobacteria-Bifidobacterium (CTCCTGGAAACGGGGTGGGGTGTTCTTCCCGATATCTACA),&#xD;
&#xD;
             5. Proteobacteria-E.Coli (CATGCCGCGTGTATGAAGAACGGGTAACGTCAATGAGCAAA)&#xD;
&#xD;
      Protection of Human subject according to Helsinki Declaration&#xD;
&#xD;
        1. Participants are allowed to receive the information of research including purpose,&#xD;
           possible intervention, and side effects.&#xD;
&#xD;
        2. Possible side effect including :&#xD;
&#xD;
        3. Participants are allowed to withdraw from the study for any reason.&#xD;
&#xD;
      Statistical Analysis Plan&#xD;
&#xD;
        1. Descriptive statistic of the baseline&#xD;
&#xD;
        2. The bivariate analysis between all variables and the outcomes&#xD;
&#xD;
        3. Paired t-test is intended to see the difference between microbiota profile, LPS, and ZO1&#xD;
           within groups&#xD;
&#xD;
        4. The independent-test to measure the difference in microbiota profile, LPS, and ZO1 value&#xD;
           between groups&#xD;
&#xD;
        5. Alternative statistical test: Linear mixed model to adjust the fixed and random effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a non-randomized trial is implemented involving three arms consists of an obese group as the intervention and two control groups, people with normal Body Mass Index, and Obese.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>To blind the participant, the mixture is given in the darker bottle, and placebo is given the artificial taste similar to the intervention group. This adjustment also blinds the care provider. The outcome assessor is blinded from the allocation of the group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Lipopolysaccharide (LPS) level of Serum</measure>
    <time_frame>Changes of LPS value from baseline to the last day of intervention (three weeks)</time_frame>
    <description>Measured using Enzyme-Linked Immunosorbent Assay (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiota Level in Stool sample</measure>
    <time_frame>Changes of Microbiota value from baseline to the last day of intervention (three weeks)</time_frame>
    <description>Measured using primary PCR of total microbiota, Firmicutes-Lactobacillus, Bacteroidetes-Bacteroides fragilis, Actinobacteria-Bifidobacterium and Proteobacteria-E.Coli</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Zonula Occludens 1 (ZO1) serum level</measure>
    <time_frame>Changes of ZO1 value from baseline to the last day of intervention (three weeks)</time_frame>
    <description>Measured using Enzyme-Linked Immunosorbent Assay (ELISA)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obese with Oryza sativa extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The group with a body mass index of more than 25 kg/m2 that receive the Oryza Sativa Extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese with control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The group with a body mass index of more than 25 kg/m2 that receive the citric acid and sorbitol mixture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Body Mass Index</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The group with a body mass index of less than 25 kg/m2 that receive the citric acid and sorbitol mixture</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oryza Sativa Extract</intervention_name>
    <description>The product is a suspension of 5.6 gram/100 mL given once daily, contains 71.9%, purple in color, range pH 3-5. Stored in the darker bottle. The frequency of administration is once-daily after the meal.</description>
    <arm_group_label>Obese with Oryza sativa extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>citric acid 0.1g/oz and 1% sorbitol mixture, given once daily after meal</description>
    <arm_group_label>Normal Body Mass Index</arm_group_label>
    <arm_group_label>Obese with control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. No consumption of the antioxidant supplement&#xD;
&#xD;
          2. No consumption of prebiotic and probiotic&#xD;
&#xD;
          3. Currently not undergo specific diet&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Current smoker&#xD;
&#xD;
          2. Diagnosed with chronic diseases&#xD;
&#xD;
          3. Patients with altered kidney and liver function&#xD;
&#xD;
          4. Unable to participate for any reason&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agussalim Bukhari, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasanuddin University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nurpudji Taslim, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasanuddin University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aminuddin Aminuddin, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasanuddin University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armanto Makmun, M.Kes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitas Muslim Indonesia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rachmat Syamsu, M.Kes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitas Muslim Indonesia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bumi Herman, MD. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bumi Herman, Ph.D</last_name>
    <phone>+66638275008</phone>
    <email>bumiherman@med.unhas.ac.id</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hasanuddin University Medical Research Center / HUMRC</name>
      <address>
        <city>Makassar</city>
        <state>South Sulawesi</state>
        <zip>90245</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Armanto Makmun, M.Kes</last_name>
      <phone>+6285299900032</phone>
      <email>armanto.makmun@umi.ac.id</email>
    </contact>
    <contact_backup>
      <last_name>Rachmat Syamsu, M.Kes</last_name>
      <phone>+6285242150099</phone>
      <email>rachmatfaisal.syamsu@umi.ac.id</email>
    </contact_backup>
    <investigator>
      <last_name>Armanto Makmun, M.Kes</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agussalim Bukhari, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aminuddin Aminuddin, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nurpudji A Taslim, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachmat F Syamsu, M.Kes</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bumi Herman, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Aguirre M, Venema K. Does the Gut Microbiota Contribute to Obesity? Going beyond the Gut Feeling. Microorganisms. 2015 Apr 27;3(2):213-35. doi: 10.3390/microorganisms3020213. Review.</citation>
    <PMID>27682087</PMID>
  </reference>
  <reference>
    <citation>Angelakis E, Armougom F, Million M, Raoult D. The relationship between gut microbiota and weight gain in humans. Future Microbiol. 2012 Jan;7(1):91-109. doi: 10.2217/fmb.11.142. Review.</citation>
    <PMID>22191449</PMID>
  </reference>
  <reference>
    <citation>Tehrani AB, Nezami BG, Gewirtz A, Srinivasan S. Obesity and its associated disease: a role for microbiota? Neurogastroenterol Motil. 2012 Apr;24(4):305-11. doi: 10.1111/j.1365-2982.2012.01895.x. Epub 2012 Feb 20. Review.</citation>
    <PMID>22339979</PMID>
  </reference>
  <reference>
    <citation>Tan J, Li Y, Hou DX, Wu S. The Effects and Mechanisms of Cyanidin-3-Glucoside and Its Phenolic Metabolites in Maintaining Intestinal Integrity. Antioxidants (Basel). 2019 Oct 12;8(10). pii: E479. doi: 10.3390/antiox8100479. Review.</citation>
    <PMID>31614770</PMID>
  </reference>
  <reference>
    <citation>Morais CA, de Rosso VV, Estadella D, Pisani LP. Anthocyanins as inflammatory modulators and the role of the gut microbiota. J Nutr Biochem. 2016 Jul;33:1-7. doi: 10.1016/j.jnutbio.2015.11.008. Epub 2015 Nov 26. Review.</citation>
    <PMID>27260462</PMID>
  </reference>
  <reference>
    <citation>Min SW, Ryu SN, Kim DH. Anti-inflammatory effects of black rice, cyanidin-3-O-beta-D-glycoside, and its metabolites, cyanidin and protocatechuic acid. Int Immunopharmacol. 2010 Aug;10(8):959-66.</citation>
    <PMID>20669401</PMID>
  </reference>
  <reference>
    <citation>Lee B, Moon KM, Kim CY. Tight Junction in the Intestinal Epithelium: Its Association with Diseases and Regulation by Phytochemicals. J Immunol Res. 2018 Dec 16;2018:2645465. doi: 10.1155/2018/2645465. eCollection 2018. Review.</citation>
    <PMID>30648119</PMID>
  </reference>
  <reference>
    <citation>Ito VC, Lacerda LG. Black rice (Oryza sativa L.): A review of its historical aspects, chemical composition, nutritional and functional properties, and applications and processing technologies. Food Chem. 2019 Dec 15;301:125304. doi: 10.1016/j.foodchem.2019.125304. Epub 2019 Jul 31. Review.</citation>
    <PMID>31394335</PMID>
  </reference>
  <reference>
    <citation>Igwe EO, Charlton KE, Probst YC, Kent K, Netzel ME. A systematic literature review of the effect of anthocyanins on gut microbiota populations. J Hum Nutr Diet. 2019 Feb;32(1):53-62. doi: 10.1111/jhn.12582. Epub 2018 Jul 8.</citation>
    <PMID>29984532</PMID>
  </reference>
  <reference>
    <citation>Hersoug LG, Møller P, Loft S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obes Rev. 2016 Apr;17(4):297-312. doi: 10.1111/obr.12370. Epub 2015 Dec 29. Review.</citation>
    <PMID>26712364</PMID>
  </reference>
  <reference>
    <citation>Bae IY, An JS, Oh IK, Lee HG. Optimized preparation of anthocyanin-rich extract from black rice and its effects on in vitro digestibility. Food Sci Biotechnol. 2017 Aug 28;26(5):1415-1422. doi: 10.1007/s10068-017-0188-x. eCollection 2017.</citation>
    <PMID>30263677</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasanuddin University</investigator_affiliation>
    <investigator_full_name>Bumi Herman</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <keyword>Lipopolysaccharide</keyword>
  <keyword>Zonula Occludens 1</keyword>
  <keyword>Obesity</keyword>
  <keyword>Oryza sativa</keyword>
  <keyword>Anthocyanin</keyword>
  <keyword>Intestinal Microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only protocol could be shared for public</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

